| Micro-channel |
 |
|
|
|
|
|
| |
| The cost inversion has caused the controversy of the low price bidding |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-8-17 15:11:16 Number Browse：712 |
| |
On August 17, the pharmaceutical network rendited the phenomenon of corporate rendition. Recently, and hubei province of Inner Mongolia YaoXie procurement platform has been published on the Inner Mongolia autonomous region medicine procurement network disqualified from the net drug notice, "the hubei province enterprises apply for revocation of net information bulletin", according to statistics, a total of 124 drugs to cancel both the net.
Previously, the two cities in sichuan province and gansu province canceled some of the drug network to attract market attention. For enterprise of withdrawal, third party medical service platform MaiSiKang lai Shi Lichen founder to the "securities daily" reporters, one is because the bidding price is lower, and the rise in raw material, artificial, taxes and other enterprises face, appear the phenomenon of cost down and unable to continue production. "In addition, drug tenders have been completed in some areas and areas that have not completed tenders will be consulted elsewhere. In order to keep market prices in key areas, enterprises have to implement the strategy of withdrawal.
More than 100 drug withdrawal marks
Released on August 14, Inner Mongolia the medicine procurement network disqualified from the net pharmaceuticals notice shows that since January 1, 2017 to July 30, 2017, due to higher raw material, production line modification, such as environmental pollution causes many drugs to stop production, there are 27 pharmaceutical production enterprise (agent) to qualify for the proposed to cancel this netting, 55 drugs involved. According to the reporter's inquiry, fang sheng pharmaceutical, kangzhi pharmaceutical, bicheng pharmaceutical and other listed companies are listed among the products.
On August 15, hubei YaoXie centralized purchasing service platform released the enterprises apply for revocation of net information bulletin, a total of 69 drug plans to cancel hang net, including the sinopharm, bayer, xinhua pharmaceutical, Chen xin pharmaceutical large drug firms such as its products.
Previously, on June 27, sichuan province's pharmaceutical centralized purchasing service center issued a notice saying that 424 pharmaceutical products that had voluntarily applied for the withdrawal of enterprises were withdrawn from the network. On the same day, the public resource trading bureau of gansu province issued a notice concerning the cancellation of the qualification for the cancellation of some medicines in some medicines (16th batch).
However, for the company that withdrew the target, Inner Mongolia is relatively strict. Which require companies to submit will not supply of national unity, enterprise must promise: "application for exit for the drug released in Inner Mongolia to exit the results, if there is supply in other provinces and cities, will be on record list and accept the service center of Inner Mongolia medicine instrument centralized purchasing in accordance with the Inner Mongolia autonomous region YaoXie centralized purchasing record management method" processing ".
To this phenomenon, one of the pharmaceutical listed company executives to the "securities daily" reporters that enterprise it was helpless, some parts of the tender price is far below the cost of production enterprises, enterprises have to give up the market.
Drug and shortage drugs are "very hurt"
It is worth mentioning that the drug involved in corporate withdrawal includes many common medicines and shortages. For example, the compound cold tablet, infantile fever cough oral liquid, dexamethasone sodium phosphate injection, montmorillonite and so on, these belong to common medicine, low - priced medicine.
On the one hand, the bidding price has been lowered, the phenomenon of enterprises abandoning bid has been repeatedly appeared, and on the one hand, it has issued the warning information for shortage.
"Companies can't see the expected profits, they have to give up the market and even stop the production of drugs." A medical industry person introduced to the reporter.
It is understood that since May 2016, relying on the national medicine GuanPing units, the government established the drug shortages in the national monitoring system, including the medical and health institutions as the object of sentinel surveillance and province centralized purchasing platform as the platform of monitoring objects. According to statistics released in April 2017, a total of 1,218 shortages were uploaded to 546 sentinel points, involving 512 varieties. A total of 658 products were uploaded on 27 provincial platforms, involving 438 varieties. There are 175 species in common shortage of sentinel and provincial platforms. The average shortage of medicines for all manufacturers is 5.3 months, of which 350 are national basic drugs, accounting for 53.1 percent.
The supply of medicines for shortage has attracted the attention of the government. However, "even if some areas have raised the purchase price of some shortages, companies are not willing to continue production or supply." The medical professionals told reporters.
"This is putting pressure on the very low price theory." 'what's more interesting is that some companies have low bid prices, and in order to maintain profits, they must reduce the quality of their products,' Mr. Shi told reporters. "The patient was ultimately injured."
"It is recommended that companies with common medicines and low-price drugs declare the cost of production and set the bid price on the basis of guaranteed profits." "He said.
The act of "letting go.
Mr. Shi told reporters that another reason for the phenomenon of corporate abandonment is to keep market prices.
According to the Inner Mongolia autonomous region YaoXie centralized purchasing record management method ", were included in the tender and bid record of enterprise, the enterprise will be cancelled all the products in the autonomous region medicine mining platform trading qualifications, since the date of announced two years not to accept the enterprise and its legal representative to participate in the centralized purchasing application, within 2 years of public medical and health institutions at various levels shall not purchase any form of its products, has signed a procurement contract since the date of announced record contract terminate itself.
That means 55 drugs from the 27 companies listed above will not be available to public hospitals in other areas. If this happens, it will lose the Inner Mongolia market.
Mr Shi believes that companies that have abandoned their targets will either change their sales channels, such as switching to retail, or sell them in public hospitals elsewhere, giving up the Inner Mongolia market.
"Under the tender state and hospital under the influence of the second negotiation, some of the products of the company is facing A number of regional market prices fall, some areas implement the national minimum price linkage, in A low price, B area will follow, enterprise in order to keep the market price, profit, had to give up some regional markets." Executives from listed companies told reporters.
|
| |
Previous article：Domestic innovative medicine first access to health insurance drug negotiations the embarrassing situation
Next article：Great impact! Again, the consumables regulation, price, distribution business should be unified
|
| |
|
|
